Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Orthocell Ltd ( (AU:OCC) ).
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options through McNulty Family Pty Ltd, exercisable at $1.53 and expiring on August 31, 2028. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and stakeholder relations positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on regenerative medicine. The company specializes in developing and commercializing products for the repair and regeneration of soft tissue injuries, targeting markets such as orthopedics and sports medicine.
Average Trading Volume: 619,748
Technical Sentiment Signal: Buy
Current Market Cap: A$292.5M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.